Atlas Trials

Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC

Clinical trial NCT07769827 · RECRUITING

Trial details

NCT number
NCT07769827
Sponsor
Jinling Hospital, China
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
HBV-HCCUnresectable Advanced HBV-related Liver Cancer
Start date
2025-12-26
Primary completion
2028-03-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.